Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
about
Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthaseDonor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia.Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantationAllogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profilePretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcomeAllo-SCT using BU, CY and melphalan for children with AML in second CR.
P2860
Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Long-term outcomes in patients ...... ioning of BU, etoposide and CY
@ast
Long-term outcomes in patients ...... ioning of BU, etoposide and CY
@en
type
label
Long-term outcomes in patients ...... ioning of BU, etoposide and CY
@ast
Long-term outcomes in patients ...... ioning of BU, etoposide and CY
@en
prefLabel
Long-term outcomes in patients ...... ioning of BU, etoposide and CY
@ast
Long-term outcomes in patients ...... ioning of BU, etoposide and CY
@en
P2093
P2860
P356
P1476
Long-term outcomes in patients ...... ioning of BU, etoposide and CY
@en
P2093
L Johnston
P2860
P2888
P304
P356
10.1038/BMT.2010.114
P407
P577
2010-05-24T00:00:00Z